264 related articles for article (PubMed ID: 25955571)
1. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Zhang Z; Cao C; Sun S; Xu Q
Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
4. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
5. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
[TBL] [Abstract][Full Text] [Related]
7. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
8. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
9. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis.
Zhang L; Dong Y; Zou F; Wu M; Fan C; Ding Y
Int Immunopharmacol; 2013 Nov; 17(3):489-94. PubMed ID: 23938253
[TBL] [Abstract][Full Text] [Related]
10. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.
Toh ML; Bonnefoy JY; Accart N; Cochin S; Pohle S; Haegel H; De Meyer M; Zemmour C; Preville X; Guillen C; Thioudellet C; Ancian P; Lux A; Sehnert B; Nimmerjahn F; Voll RE; Schett G
Arthritis Rheumatol; 2014 Nov; 66(11):2989-3000. PubMed ID: 24623505
[TBL] [Abstract][Full Text] [Related]
11. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
[TBL] [Abstract][Full Text] [Related]
12. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
Paniagua RT; Sharpe O; Ho PP; Chan SM; Chang A; Higgins JP; Tomooka BH; Thomas FM; Song JJ; Goodman SB; Lee DM; Genovese MC; Utz PJ; Steinman L; Robinson WH
J Clin Invest; 2006 Oct; 116(10):2633-42. PubMed ID: 16981009
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
14. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Konda VR; Desai A; Darland G; Bland JS; Tripp ML
Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis.
Krausz S; Garcia S; Ambarus CA; de Launay D; Foster M; Naiman B; Iverson W; Connor JR; Sleeman MA; Coyle AJ; Hamann J; Baeten D; Tak PP; Reedquist KA
Ann Rheum Dis; 2012 Aug; 71(8):1402-10. PubMed ID: 22730375
[TBL] [Abstract][Full Text] [Related]
16. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
[TBL] [Abstract][Full Text] [Related]
17. Oleanolic acid acetate inhibits rheumatoid arthritis by modulating T cell immune responses and matrix-degrading enzymes.
Choi JK; Kim SW; Kim DS; Lee JY; Lee S; Oh HM; Ha YS; Yoo J; Park PH; Shin TY; Kwon TK; Rho MC; Kim SH
Toxicol Appl Pharmacol; 2016 Jan; 290():1-9. PubMed ID: 26570984
[TBL] [Abstract][Full Text] [Related]
18. Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis.
Ozaki N; Suzuki S; Ishida M; Harada Y; Tanaka K; Sato Y; Kono T; Kubo M; Kitamura D; Encinas J; Hara H; Yoshida H
Int Immunol; 2012 Sep; 24(9):539-50. PubMed ID: 22914861
[TBL] [Abstract][Full Text] [Related]
19. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis.
Murakami Y; Akahoshi T; Aoki N; Toyomoto M; Miyasaka N; Kohsaka H
Arthritis Rheum; 2009 Jun; 60(6):1615-23. PubMed ID: 19479878
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts.
Mun SH; Kim JW; Nah SS; Ko NY; Lee JH; Kim JD; Kim DK; Kim HS; Choi JD; Kim SH; Lee CK; Park SH; Kim BK; Kim HS; Kim YM; Choi WS
Arthritis Rheum; 2009 Mar; 60(3):678-85. PubMed ID: 19248119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
